The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 879-890

  Palayekar, M J ^a   Herzog, T J ^b  

^a SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

EGFR inhibitors; Monoclonal antibodies; Ovarian cancer; Small molecule tyrosine kinase inhibitors

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANASTROZOLE; ANTHRACYCLINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; PLACEBO; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LIVER CELL CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIGANDS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 51749099175     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01144.x     Document Type: Review

References (78)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2007. CA Cancer J Clin 2007 57 : 43 66.
2. Staging announcement: FIGO Cancer Committee. Gynecol Oncol 1986 25 : 383 5.
3. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003 88 : 58.
4. Surveillance Program, Division of Cancer Prevention and Control. Cancer statistics review, 1973-87. Washington, DC : National Cancer Institute, 1988. Publication No. 90-2789.
5. Young RC, Decker DG, Wharton JT et al. Staging laparotomy in early ovarian cancer. JAMA 1983 250 : 3072.
6. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996 334 : 1 6.
7. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001 2 : 4 11.
8. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001 7 : 2958 70.
9. Arteaga C. Overview of epidermal growth factor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002 29 (5 Suppl. 14 38 44.
10. Bunn PA, Franklin W. Epidermal growth factor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002 29 (5 Suppl. 14 38 44.
11. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003 4 : 397 406.
12. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995 55 : 5536 9.
13. Alper O, Bergmann-Leitner ES, Hacker NF et al. Epidermal growth factor receptor signaling and the invasive phenotype in ovarian cancer cells. J Natl Cancer Inst 2001 93 : 1375 84.
14. Skirnisdottir I, Sorbe B, Seidal T. The growth factors HER-2/neu and EGFR, their relationship, and their effects on the prognosis of early stage epithelial ovarian cancer. Int J Gynecol Cancer 2001 11 : 199 29.
15. Chen Z, Fadial A, Feng Y et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and erzin translocation are stimulated by interleukin-1a and epidermal growth factor receptor. Cancer 2001 142 : 2776 88.
16. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004 30 : 225 68.
17. Shin DM, Nemunaitis J, Zinner RG et al. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors abstract Proc Am Soc Clin Oncol 2001 20. Abstract 324.
18. Garrison MA, Tolcher A, McCreery H et al. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors abstract Proc Am Soc Clin Oncol 2001 20. Abstract 283.
19. Zinner RG, Donato NJ, Nemunaitis JJ et al. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033 abstract Proc Am Soc Clin Oncol 2002 21. Abstract 58.
20. Olson SC, Baker L, Cunningham CC et al. A population pharmacokinetic (PPK) analysis of oral CI-1033, a pan-arbB tyrosine kinase inhibitor, in patients with 32 advanced solid tumors abstract Proc Am Soc Clin Oncol 2002 21. Abstract 361.
21. Rinehart JJ, Wilding G, Willson J et al. A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors abstract Proc Am Soc Clin Oncol 2002 21. Abstract 41.
22. Rowinsky EK, Garrison M, Lorusso P et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: a phase I, pharmacokinetic (PK), and food effect study. Proc Am Soc Clin Oncol 2003 22. Abstract 807.
23. Rinehart JJ, Wilding G, Willson J et al. A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors abstract Proc Am Soc Clin Oncol 2003 22. Abstract 821.
24. Nemunaitis JJ, Eiseman I, Cunningham C et al. A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors abstract Proc Am Soc Clin Oncol 2003 22. Abstract 974.
25. Simon GR, Olson S, Garrett CR et al. Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors 31 abstract J Clin Oncol 2004 22 (14S 3057.
26. Eder JP, Hidalgo M, Mendelson D et al. A phase I clinical and pharmacokinetic (PK) study of oral CI-1033 + docetaxel (DOC) in the treatment of patients with advanced solid tumors abstract J Clin Oncol 2005 23 (16S 3111.
27. Swaisland H, Laight A, Stafford L et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinases inhibitor ZD 1839 in healthy volunteers. Clin Pharmacokinet 2001 40 : 297 306.
28. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types. J Clin Oncol 2002 20 : 4292 302.
29. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of phase I trial. J Clin Oncol 2002 20 : 3815 25.
30. Ranson M, Hammond LA, Ferry D et al. ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002 20 : 2240 50.
31. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in Japanese patients with solid tumors. Ann Oncol 2003 14 : 922 30.
32. Slomovitz BM, Coleman RL, Levenback C et al. Phase I study of weekly topotecan and gefitinib in patients with platinum resistant ovarian, peritoneal or fallopian tube cancer. J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 2006 24 (Suppl 5090.
33. Hariprasad R, Kumar L, Patnaik R, Gupta A, Kumar S. Maintenance therapy in epithelial ovarian cancer (EOC): could EGFR inhibitor-gefitinib be a candidate drug? A pilot study. J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 2006 24 (Suppl 15046.
34. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005 11 : 5539 48.
35. Mavroudis D, Efstathiou E, Polyzos A et al. Phase I to II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer abstract Proc ASCO 2004 22 (14S 5020.
36. Vergote IB, Humblet Y, Vancutsem E et al. A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor positive solid tumors who had failed previous chemotherapy: interim data. J Clin Oncol (2005 Proc ASCO) 2005 23 (Pt I/II Suppl 2005 : 3162.
37. Krasner CN, Debernardo RL, Findley M et al. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol (Proc ASCO 2005) 2005 23 : 5063.
38. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Eng J Med 2004 350 : 2129 39.
39. Paez JG, Janne PA, Lee JC et al. Epidermal growth factor receptor mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500.
40. Strother RM, Jones DR, Skaar T et al. Erlotinib associated rash correlates with plasma levels at steady state. J Clin Oncol (Proc ASCO 2006) 2006 24 : 13008.
41. All LF, Cerna C, Gomez L et al. Investigation of the effects of CP-358,774 (OSI 0774) on various human tumor specimens taken directly from patients abstract Proceedings of the 11th NCI-EORTC-AACR Symposium on new drugs in Cancer therapy; November 7-10, 2000 Amsterdam, The Netherlands.
42. Pollack VA, Savage DM, Baker DA et al. Inhibition of EGFR associated tyrosine phosphorylation in human carcinomas with CP-358,774. J Pharmacol Exp Ther 1999 291 : 739 48.
43. Hidalgo M, Sui LL, Nemunaitis J et al. Phase I and pharmacokinetic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001 19 : 3267 79.
44. Karp DD, Silberman R, Csudae R et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors abstract Proc Am Soc Clin Oncol 1999 16. Abstract 1499.
45. Finkler N, Gordon A, Crozier M et al. Phase II evaluation of OSI-774, a potent 29 oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma abstract Proc Am Soc Clin Oncol 2001 20. Abstract 831.
46. Vasey P, Kaye S, Paul J et al. A phase IB trial of erlotinib in combination with docetaxel and carboplatin in untreated ovarian, fallopian tube and primary peritoneal cancers abstract J Clin Oncol 2004 22 (14S 5017.
47. Blank SV, Curtin JP, Goldman NA et al. Report of first stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first line treatment of ovarian cancer. J Clin Oncol (Proc ASCO 2006) 2006 24 : 5076.
48. Perez-Soler R, Zou Y, Li T et al. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab induced EGFR inhibition in the skin. J Clin Oncol (2006 Proc ASCO) 2006 24 : 3036.
49. Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep 2005 7 : 241 7.
50. Von Eyben FE. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 2006 43 : 291 323.
51. Chu Q, Goldstein L, Murray N et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. J Clin Oncol 2005 23 (16S 3001.
52. Minami H, Nakagawa K, Kawada K et al. A phase I study of GW572016 in patients with solid tumors abstract J Clin Oncol 2004 22 (14S 3048.
53. Versola M, Burris HA, Jones S et al. Clinical activity of GW572016 in EGF 10003 in patients with solid tumors abstract J Clin Oncol 2004 22 (14S 3047.
54. Jones SF, Hainsworth JD, Spigel DR et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 2004 22 (14S 2083.
55. Adams VR, Bence AK, Anderson EB et al. A phase I pharmacokinetic/ pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects abstract Proc Am Soc Clin Oncol 2002 21. Abstract 374.
56. Ravaud A, Gardner J, Hawkins R, Von der Maase H, Zantl N et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 2006 24 (Suppl 4502.
57. Campos SM, Seiden MV, Oza A et al. A phase II, single-agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy abstract Proc ASCO 2004.
58. Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 2003 41 : S43 8.
59. Dumez H, Hoekstra R, Eskens F et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer abstract Proc ASCO 2002 21. Abstract 341.
60. Murren JR, Papadimitrakopoulou VA, Sizer KC et al. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers abstract Proc ASCO 2002 21. Abstract 377.
61. Hoekstra R, Dumez H, Van Oosterom AT et al. A phase I and pharmacological study of PKI166, an EGFR tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer abstract Proc ASCO 2002 21. Abstract 340.
62. Hidalgo M, Erlichman C, Rowinsky EK et al. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors abstract Proc ASCO 2002 21. Abstract 65.
63. Morgan JA, Bukowski RM, Xiong H et al. Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the EGFR, given in combination with gemcitabine to patients with advanced pancreatic cancer abstract Proc ASCO 2003 22. Abstract 788.
64. Salazar R, Kohne CH, Tabernero J et al. A phase 1/2A open-label study of EKB-569 in combination with CPT-11/5-FU/LV (FOLFIRI) in patients with advanced colorectal cancer abstract Proc ASCO 2003 22. Abstract 888.
65. Natarajan M, Roldan FA, Sheriff H et al. EKB-569 attenuates radiation triggered survival response in squamous cell carcinoma abstract Proc ASCO 2003 22. Abstract 993.
66. Casado E, Folprecht G, Paz-Ares L et al. A phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with5-FU, leucovorin and irinitecan (CPT-11) (FOLFIRI regimen) in patients with advanced colorectal cancer. J Clin Oncol (2004 ASCO Proc) 2004 22 (Suppl 3543.
67. Tejpar S, Van Cutsem E, Gamelin E et al. Phase i/2a study of EKB-569, an irreversible inhibitor of EGFR, in combination with 5-FU, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer. J Clin Oncol 2004 22 (Suppl 3579.
68. Pegrem M. Current status of tyrosine kinase inhibitors in the treatment of lung cancer. Clin Adv Hematol Oncol 2006 4 (Suppl. 24): 1 12.
69. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or 34 refractory ovarian or primary peritoneal carcinoma with over expression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003 21 : 283 90.
70. Aghajanian C, Sabbatini P, Derosa F et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer abstract J Clin Oncol 2005 23 (16S 5047.
71. Tewes M, Schleucher N, Dirsch O et al. Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors abstract Proc Am Soc Clin Oncol 2002 21. Abstract 378.
72. Yang X, Xiao-chi J, Corvalan J et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment abstract Proc Am Soc Clin Oncol 2000 19. Abstract 183.
73. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004 22 : 3003 15.
74. Glenn D, Ueland F, Bicher A et al. A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): preliminary safety data abstract J Clin Oncol 2006 24 (18S 13001.
75. Allison DE, Ng C, Derynck MK et al. Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and 35 lung cancers abstract J Clin Oncol 2005 25 (16S 2532.
76. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship between tumor HER2 activation status. J Clin Oncol 2006 24 : 4324 32.
77. Tanner B, Hasenclever D, Stern K et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006 24 : 4317 23.
78. Amann J, Kalyankrishna S, Masslon PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005 65 : 226 35.